Fennec Pharmaceuticals Supports New Trial for Hearing Loss Prevention in Cancer Treatment

Fennec Pharmaceuticals ( (TSE:FRX) ) has shared an announcement.

Fennec Pharmaceuticals announced an investigator-sponsored trial by City of Hope to evaluate PEDMARK® for preventing hearing loss in adult men with metastatic testicular germ cell tumors undergoing cisplatin-based chemotherapy. This study highlights the increasing clinical interest in mitigating the long-term quality-of-life impacts of chemotherapy-induced hearing loss, potentially expanding the use of PEDMARK® into metastatic disease contexts.

The most recent analyst rating on (TSE:FRX) stock is a Buy with a C$13.00 price target. To see the full list of analyst forecasts on Fennec Pharmaceuticals stock, see the TSE:FRX Stock Forecast page.

Spark’s Take on TSE:FRX Stock

According to Spark, TipRanks’ AI Analyst, TSE:FRX is a Neutral.

Fennec Pharmaceuticals shows strong revenue growth and improved cash flow, key for its industry. However, profitability issues and a weak balance sheet weigh down the score. Technical indicators and valuation reflect mixed signals, while positive earnings call sentiments provide some optimism. Addressing financial challenges will be crucial for future performance.

To see Spark’s full report on TSE:FRX stock, click here.

More about Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing therapies to address unmet medical needs, particularly in the area of oncology. Their primary product, PEDMARK®, is approved for reducing the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic solid tumors.

Average Trading Volume: 1,214

Technical Sentiment Signal: Buy

Current Market Cap: C$359.8M

See more insights into FRX stock on TipRanks’ Stock Analysis page.